Corvus Pharmaceuticals, Inc. (CRVS) Reports In-Line Q1 EPS
Tweet
Share
E-mail
Get Alerts CRVS Hot Sheet
Join SI Premium – FREE
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) reported Q1 EPS of ($0.15), in-line with the analyst estimate of ($0.15). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .
For earnings history and earnings-related data on Corvus Pharmaceuticals, Inc. (CRVS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Bernstein on U.S. telecom: "Another strong quarter"
- Terra Innovatum Global N.V. (NKLR) Misses Q2 EPS by 12c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
